We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Conditions for Mixing, Diluting or Repackaging Biologics
FDA Clarifies Conditions for Mixing, Diluting or Repackaging Biologics
The FDA issued final guidance on approved biologics that are mixed, diluted or repackaged, noting when the agency will not take action against violations of its standard rules on product misbranding and false and misleading labeling.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor